TP53 and therapy-related myeloid neoplasms. Issue 1 (March 2019)

• Record Type: Journal Article
• Authors: Chung, Jae; Sallman, David A.; Padron, Eric
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 32:Issue 1(2019)
• Page Start: 98
• Page End: 103
• Publication Date: 2019-03
• Subjects: Therapy-related myelodysplastic syndrome (t-MDS) -- Therapy-related acute myeloid leukemia (t-AML) -- Next-generation sequencing (NGS) -- TP53; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2019.02.009
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Therapy-related myeloid neoplasms ( t -MNs) are the most serious late complications in patients treated with traditional cytotoxic chemotherapy and/or radiation. T-MNs are aggressive and chemorefractory hematologic malignancies, with a median survival of less than 6 months. TP53 mutations are highly enriched in t-MN patients, though the mechanism for this selective enrichment has only come to light over the past several years. In this review, we discuss the history and function of p53, and the role of TP53 mutations in the origin and progression of t -MNs. Emerging data has begun to elucidate who may be at highest risk of developing t -MNs, which ideally will enable us to develop preventative strategies for this devastating disease. As t -MNs may not be avoidable, novel therapies are urgently needed for this patient group and are underway as exemplified by recent investigation in restoring wild-type p53 function as well as directly targeting TP53 mutant variants. With better prevention and treatment, outcomes will hopefully begin to improve in the near future.